• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    11/14/24 5:46:12 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GPCR alert in real time by email
    SC 13G/A 1 tm2427451d30_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Structure Therapeutics Inc.

    (Name of Issuer)

     

    Ordinary Shares, par value $0.0001 per share

    (Title of Class of Securities)

     

    86366E106**

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)
      x Rule 13d-1(c)
      ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **CUSIP number 86366E106 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Market under the symbol “GPCR.” Each ADS represents three Ordinary Shares of the Issuer. No CUSIP has been assigned to the Issuer’s Ordinary Shares.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No.    86366E106
    1

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    5,690,316

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    5,690,316

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,690,316

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    3.3%

    12

    Type of Reporting Person (See Instructions)

     

    IA, PN

           

     

     

    CUSIP No.   86366E106
    1

    Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    5,690,316

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    5,690,316

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,690,316

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    3.3%

    12

    Type of Reporting Person (See Instructions)

     

    HC, IN

           

     

     

    CUSIP No.   86366E106
    1

    Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    5,690,316

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    5,690,316

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,690,316

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    3.3%

    12

    Type of Reporting Person (See Instructions)

     

    HC, IN

           

     

     

     

    CUSIP No.   86366E106
    1

    Names of Reporting Persons
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ¨

    (b) ¨

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    5,690,316

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    5,690,316

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    5,690,316

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    3.3%

    12

    Type of Reporting Person (See Instructions)

     

    PN

           

     

     

     

    Item 1(a).Name of Issuer:

     

        Structure Therapeutics Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

         601 Gateway Blvd., Suite 900, South San Francisco, CA 94080

     

    Item 2(a).Names of Persons Filing:

     

        The names of the persons filing this report (collectively, the “Reporting Persons”) are:

     

        RA Capital Management, L.P. (“RA Capital”)

        Peter Kolchinsky

        Rajeev Shah

        RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

        The address of the principal business office of each of the Reporting Persons is:

     

        c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

        RA Capital and the Fund are Delaware limited partnerships.

        Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

        Ordinary Shares, par value $0.0001 per share (“Ordinary Shares”)

     

    Item 2(e).CUSIP Number:

     

        86366E106

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

         Not applicable.

     

    Item 4.Ownership.

     

      The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G/A. The ownership percentages reported are based on 171,589,531 Ordinary Shares outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024.
       
      The Fund directly holds 1,896,772 American Depositary Shares (“ADSs”) of the Issuer, representing an aggregate of 5,690,316 Ordinary Shares. Each ADS represents three Ordinary Shares of the Issuer.

     

     

     

      RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund’s portfolio, including the ADSs representing Ordinary Shares of the Issuer reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days’ notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

        Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

        Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

        Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

        Not applicable.

     

    Item 10.Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

    Exhibit List

     

    Exhibit 1:             Joint Filing Agreement

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its or his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024  
       
    RA CAPITAL MANAGEMENT, L.P.  
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Authorized Signatory  
       
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
       
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
       
    RA CAPITAL HEALTHCARE FUND, L.P.  
       
    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
       
    By: /s/ Peter Kolchinsky  
      Name: Peter Kolchinsky  
      Title: Manager  

     

    Get the next $GPCR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GPCR

    DatePrice TargetRatingAnalyst
    5/2/2025$60.00Buy
    Citigroup
    2/28/2025Outperform
    William Blair
    1/8/2025$50.00Buy
    Stifel
    12/4/2024$80.00Buy
    H.C. Wainwright
    9/23/2024$118.00Overweight
    Morgan Stanley
    5/21/2024$65.00Overweight
    JP Morgan
    4/9/2024$65.00Overweight
    Cantor Fitzgerald
    10/19/2023$90.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $GPCR
    SEC Filings

    View All

    Structure Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Structure Therapeutics Inc. (0001888886) (Filer)

    12/10/25 5:06:57 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Structure Therapeutics Inc.

    424B5 - Structure Therapeutics Inc. (0001888886) (Filer)

    12/10/25 5:04:01 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Structure Therapeutics Inc.

    424B5 - Structure Therapeutics Inc. (0001888886) (Filer)

    12/8/25 5:28:16 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by See Remark 1 Fmr Llc

    4 - Structure Therapeutics Inc. (0001888886) (Issuer)

    12/10/25 2:07:23 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Coll Crespo Blas covered exercise/tax liability with 8,106 units of Ordinary Shares, decreasing direct ownership by 4% to 216,807 units (SEC Form 4)

    4 - Structure Therapeutics Inc. (0001888886) (Issuer)

    9/22/25 9:25:04 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Hall Ashley covered exercise/tax liability with 6,021 units of Ordinary Shares, decreasing direct ownership by 5% to 112,317 units (SEC Form 4)

    4 - Structure Therapeutics Inc. (0001888886) (Issuer)

    9/22/25 9:25:06 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Structure Therapeutics with a new price target

    Citigroup initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $60.00

    5/2/25 8:15:19 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Structure Therapeutics

    William Blair initiated coverage of Structure Therapeutics with a rating of Outperform

    2/28/25 7:24:16 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Structure Therapeutics with a new price target

    Stifel initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $50.00

    1/8/25 7:51:31 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs

    SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the closing of its previously announced upsized underwritten public offering of 9,961,538 American depositary shares (ADSs), each representing three ordinary shares, which includes the full exercise of the underwriters' option to purchase up to 1,500,000 additional ADSs at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the secu

    12/11/25 4:01:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

    SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the pricing of its upsized underwritten public offering of 8,461,538 American depositary shares (ADSs), each representing three ordinary shares, at a price to the public of $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at a price to the public of $64.9999 per pre-funded warrant. All of the securities in the offering are being sold by Structure Therapeutics. The gross proceeds to Structure Therapeutics from the offeri

    12/9/25 11:15:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

    SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the commencement of a proposed underwritten public offering, subject to market and other conditions, to issue and sell $500 million of American depositary shares (ADSs), each representing three ordinary shares, or for certain investors that so choose, in lieu of ADSs, pre-funded warrants to purchase ordinary shares, represented by ADSs. All securities are being offered by Structure Therapeutics. In connection with the proposed offering,

    12/8/25 4:01:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Leadership Updates

    Live Leadership Updates

    View All

    Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

    SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase

    9/17/24 4:05:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Appoints Angus C. Russell to Board of Directors

    SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of Shire plc and brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry. "Structure is at an important moment in its evolution as we prepare to advance our oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity," said Raymond Steve

    8/27/24 4:05:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

    Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements. "We have continued our momentum and are on track to report topline data from our fully-enrolled Phase 2a study of GSBR-129

    8/10/23 4:05:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Financials

    Live finance-specific insights

    View All

    Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

    Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation  Placebo-adjusted mean weight loss up to 15.3% (35.5 lbs) observed with 240 mg dose in the exploratory ACCESS II study at 36 weeks No adverse event-related treatment discontinuations observed when starting at lower 2.5 mg dose in ACCESS Open Label Extension and Body Composition Study Data comprehensively support and inform advancement to Phase 3 clinical development program in mid-2026 Company to host conference call today at 8:30 a.m. Eastern Time SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutic

    12/8/25 8:00:00 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

    SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company's once-daily oral small molecule GLP-1 receptor agonist for the treatment of obesity, before the market opens on Monday, December 8, 2025. Members of management will host a conference call and webcast to discuss the data at 8:30 a.m. ET the same day. To access the live webcast, please visit the Investor Relations page of the company's website at

    12/7/25 6:20:23 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

    Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671. Amy

    12/17/24 4:01:00 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GPCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 5:46:12 PM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Structure Therapeutics Inc.

    SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 10:26:11 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

    11/14/24 9:33:27 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care